TheBodyPro | Expert analysis from Benjamin Young, M.D., Ph.D.
A new tranche of real-world data from a major Spanish study gives us further evidence that long-acting antiretroviral therapy with cabotegravir/rilpivirine (CAB/RPV) has real staying power once people switch to it. It also helps us begin to understand some of the specific reasons why CAB/RPV is sometimes unsuccessful — and gives us a sense of when that is most likely to become apparent.
Key takeaways
- In the RELATIVITY cohort, through a median two years of follow-up after switching to CAB/RPV, 89% remained on the regimen, and 97% of participants with viral load measurements were virally suppressed.
- Virologic failure occurred in 0.8% of participants, predominantly within the first year; two-thirds of these cases involved emergent drug resistance.
- These data can help clinicians individualize CAB/RPV decision-making and monitoring, including consideration of a patient’s resistance history, treatment preferences, level of access to care, and level of support for changing life circumstances.
Read the full analysis here.
Source : TheBodyPro
Related HIV and Co-Infections News
-
HIV i-Base | Injectable lenacapavir plus CAB-LA: high viral efficacy but ViiV and Gilead block further research
-
Bioengineer.org | Mobile app reduces detectable HIV viral load in men using stimulants
-
Bioengineer.org | Archived HIV resistance mutation surfaced years later to undermine long-acting therapy
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.